EVAS2 IDE Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study

INCLUSION CRITERIA A patient who meets all of the following criteria potentially may be included in the study: 1. Male or female at least 18 years old; 2. Informed consent form understood and signed 3. Patient agrees to all follow-up visits; 4. Abdominal aortic aneurysm with sac diameter ≥5.0cm, or ≥4.5cm which has increased by ≥0.5cm within the last 6 months, or or which exceeds 1.5 times the transverse dimension of an adjacent non-aneurysmal aortic segment. No AAA \<4 cm will be included. 5. Anatomically eligible for the Nellix System (per Instructions For Use): 1. Adequate iliac/femoral access compatible with the required delivery systems (diameter ≥6 mm); 2. Aneurysm blood lumen diameter ≤60mm; 3. Proximal non-aneurysmal aortic neck: length ≥10mm; diameter 18 to 28mm; angle ≤60° to the aneurysm sac; 4. Most caudal renal artery to each hypogastric artery length ≥100mm; 5. Common iliac artery lumen diameter between 9 and 35mm; 6. Distal iliac artery seal zone with length of ≥10mm and diameter range of 9 to 25mm; 7. Ability to preserve at least one hypogastric artery. 8. Ratio of maximum aortic aneurysm diameter to maximum aortic blood lumen diameter \<1.40 EXCLUSION CRITERIA A patient who meets none of the following criteria potentially may be included in the study: 1. Life expectancy \<2 years as judged by the Investigator; 2. Psychiatric or other condition that may interfere with the study; 3. Participating in another clinical study; 4. Known allergy or contraindication to any device material; 5. Coagulopathy or uncontrolled bleeding disorder; 6. Ruptured, leaking or mycotic aneurysm; 7. Serum creatinine (S-Cr) level \>2.0 mg/dL; 8. CVA or MI within three months of enrollment/treatment; 9. Aneurysmal disease of the descending thoracic aorta; 10. Clinically significant mural thrombus within the proximal landing zone (minimum 10mm) of the infrarenal non-aneurysmal neck (\>5mm thickness over \>50% circumference); 11. Connective tissue diseases (e.g., Marfan Syndrome); 12. Unsuitable vascular anatomy that may interfere with device introduction or deployment; 13. Pregnant (female of childbearing potential only).